AVR 0.00% $12.00 anteris technologies ltd

Ann: Appendix 3B, page-45

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 509 Posts.
    lightbulb Created with Sketch. 48

    I agree entirely. The only hope is a deal for TAVR with a big name. A possible hope is the 4C Alta valve which is at a more ,promising and unique position. They are tied to us and our adapt tissue. If the 4C becomes a market darling they stand to sell a1000 valves per week imho. That would be a company maker for us. Perhaps we could do a deal now with them. Give us 10 to 20m and you can have the adapt at 60% cost for 5 years. If they sold 1000 valves per week it might be worth $2m cash flow per week to us. On second thoughts perhaps we should sell the vaccines, the TAVR plus infusions and stake everything on the 4C opportunity. Sell the adapt business except for the 4C business. That would carry us through to 4C success with minimal costs . 4C is going to be a leader in a $5b annual business . Why not be part of this and this alone with a possible cash flow of $100m per annum for us. At this stage an all or none simple bet.
    My lesson learned from AHZ. I have got into a respectable company Fisher Paykel health. $8B MC, good management good board good everything that sadly AHZ is not. Expecting 12% annual price increase. Am up 8% in 3 months. DYOR.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.